India cancels licences of some drug firms in crackdown on fake products, says source

March 30, 2023 09:49 PM AEDT | By Reuters
Follow us on Google News:
Image source: Reuters

By Krishna N. Das

NEW DELHI (Reuters) - Indian authorities have cancelled or suspended licences of some domestic drug companies as part of action taken against 76 pharmaceutical firms this month for selling adulterated or fake products, a government source said on Thursday.

India is known as the 'pharmacy of the world' and its pharmaceuticals exports have more than doubled over the past decade to $24.5 billion in 2021-22.

But that image has been dented by the death of at least 70 children in Gambia and 19 children in Uzbekistan last year linked to drugs made by India-based pharmaceutical companies.

Health Minister Mansukh Mandaviya confirmed a crackdown but did not give details of companies against which action had been taken.

"There are more than 10,500 pharma companies in the country. Companies who make spurious medicine will not be spared," Mandaviya told reporters at an event.

Licences of some Indian drug companies have been canceled, some were suspended while others have been put on notice during the past 15 days, the source, who had direct knowledge of the matter, told Reuters.

The source, who did not want to be identified as they were not authorised to speak to the media, declined to reveal the names of the companies.

The federal government has said it will spend $79.6 million on strengthening its drug regulatory system after the World Health Organization raised concerns about domestically produced cough syrups being linked to the death of children in Gambia and Uzbekistan.

(Writing by Sudipto Ganguly; Editing by Frank Jack Daniel and Muralikumar Anantharaman)


The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK